2nd DECENTRALIZED & HYBRID CLINICAL TRIALS WORLD CONGRESS 2026 EUROPE
Patient-centric approach to Decentralized & Hybrid Trials: Understanding the changing landscape, the trends, challenges, and opportunities for a successful implementation.
London, United Kingdom
Day 1 - Wednesday 25th February 2026
REGULATORY GUIDELINES
- Addressing varying regulatory guidelines for DCT
- Emerging regulatory frameworks and approaches
- Potential opportunities and challenges for DCT solution providers.
- Regulations clarifying access to health technologies and technical requirements.
- Adhering with data privacy laws and compliance
- Lessons learned and future of DCTs
Moderator:
Panelist:
- Brief overview of the current guidelines
- ACT EU Pilot scheme for trials with decentralized elements
- Harmonised and transparent approach for the use of DCT elements in clinical trials.
- Review outlines of gap analysis focused on the frameworks and guidance
- The need for a comprehensive sustainability assessment of each DCT element
- Guidance related to a comprehensive assessment of designing and executing sustainable DCTs needed
- Factors stakeholders regard as having the most significant impact on driving sustainability decisions in DCTs.
CURRENT TRENDS AND STRATEGIES
- Current role of digital platforms in supporting decentralized trial activities
- Challenges and benefits of digital platforms to investigators and participants
- The obstacles developers must address before a fully integrated and unified DCT can be realized.
- New tools and framework that facilitates progressive decentralization
- Technological developments in telehealth
- Important aspects to consider when conceptualizing a phase 1 decentralized clinical trial
- Examples of promising model for early drug development.
- Current adoption of remote monitoring and data collection technologies
- Drivers of increasing adoption of remote monitoring and data collection technologies
- Remote monitoring and data collection technologies with greatest outcomes associated with patient experience
- Aspirations and direction for industry to enable more patient-centric trials.
- Ethical aspects of digitalization in clinical trials associated with digital technologies
- Informed consent in clinical research
- Decentralized informed consent procedures that are impacted by digitalization
- Electronic consenting technologies and procedures
- Opportunities and Considerations
- Data-Driven Solutions in Planning and Feasibility of Clinical Trials
- Various decentralization components available for stakeholders to increase the reach and pace of their trials
- Fit-for-Purpose, Usability Studies, and Contingencies
- Examples of trials with dual DCT and DHT components
- What is IRT and why use it for your trial?
- Greatest challenges and obstacles to consider when selecting new IRT innovations?
- Technical and operational considerations in selecting an IRT vendor
- What are the benefits to look for?
4:10 pm - PLENARY SESSION: Steering eCOA in your global DCTs: eCOA strategies positioned for success
- Perspectives and guidance for effective eCOA in global DCTs
- Preparations to implement eCOA in your global DCTs
- What are the complexities of the eCOA process
- Can technology play a pivotal role in achieving better outcomes?
- Benefits of Decentralized Clinical Trials revolutionizing the way research is conducted
- Key Components of Decentralized Trials reshaping the traditional model
- Ethical standards and participant safety as crucial cornerstones of the research effort
- Challenges and barriers in clinical research
- Principles for successful Decentralization in Clinical Trials